Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Archive of News

<< 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2013 >>

14 September 2012: UCLB signs exclusive global license with Oxford Pharmascience for colonic delivery of statins

UCLB  has entered into an exclusive licence agreement with Oxford Pharmascience Group PLC to develop and commercialise reformulation of statin molecules using the proprietary colon delivery technology (PhloralTM) developed by researchers at UCL School of Pharmacy. More...

<< 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2013 >>